IMR Press / FBE / Volume 5 / Issue 3 / DOI: 10.2741/E671

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Echocardiographic effects of eplerenone and aldosterone in hypertensive rats

Show Less
1 Central Texas Veterans Health Care System, Temple, TX, USA
2 Division of Cardiology, Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation and Cardiovascular Research Institute, Division of Molecular Cardiology, Texas A&M Health Science Center-College of Medicine, Temple, TX, USA
3 Division of Cardiology, Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation
4 Department of Clinical Data and Analytics, Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation
5 Cardiovascular Research Institute, Division of Molecular Cardiology, Texas A&M Health Science Center-College of Medicine, Temple, TX, USA

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2013, 5(3), 922–927; https://doi.org/10.2741/E671
Published: 1 June 2013
Abstract

The effects of aldosterone receptor blockade on echocardiography in spontaneously hypertensive rats (SHR) are not fully characterized. In this study, multiple echocardiographic parameters were compared for 42 weeks between SHR versus Wistar-Kyoto rats (WKY) serving as normotensive controls. In addition, echocardiographic parameters were compared for 28 weeks between the SHR versus SHR treated with eplerenone 100 mg/kg/day or spironolactone 50 mg/kg/day. Compared to normotensive WKY rats, SHRs had significantly increased systolic blood pressure, increased cardiac mass, increased isovolumic relaxation time (IVRT), decreased E/A ratio, increased mitral closure opening time interval (MCO) and increased Tei index. Both eplerenone and spironolactone significantly decreased systolic blood pressure compared to the SHR controls. The spironolactone treatment group demonstrated significant increases in heart rate and cardiac output and a decrease in cardiac index compared to SHR controls. Any aldosterone blockade in SHR protected against the increased cardiac mass. Similar to clinical echocardiographic observations, hypertension in rats results in left ventricular hypertrophy (LVH) and diastolic dysfunction and aldosterone receptor blockade reduces LVH in SHR.

Keywords
Hypertension
Echocardiography
Aldosterone Receptor Blockade
Spironolactone
Eplerenone
Share
Back to top